Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China · Delayed Price · Currency is CNY 44.68
+0.36 (0.81%)
Jul 31, 2026, 3:00 PM CST
SHA:688513 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,790 | 10,731 | 5,252 | 7,659 | 7,306 | 5,572 | |
Market Cap Growth | -28.36% | 104.34% | -31.43% | 4.83% | 31.12% | -2.50% |
Enterprise Value | 6,348 | 9,298 | 4,010 | 6,419 | 6,112 | 3,987 |
Last Close Price | 44.68 | 60.93 | 29.54 | 42.05 | 39.71 | 29.77 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 28.27 | 37.78 | 22.05 | 33.81 | 29.64 | 23.97 |
Forward PE | 26.28 | 36.07 | 16.21 | 25.33 | 22.56 | 20.69 |
PS Ratio | 5.76 | 8.06 | 3.89 | 6.86 | 6.24 | 5.45 |
PB Ratio | 2.52 | 3.53 | 1.95 | 2.94 | 2.99 | 2.43 |
P/TBV Ratio | 2.82 | 3.97 | 1.97 | 2.98 | 3.03 | 2.47 |
P/FCF Ratio | 35.34 | 60.07 | 36.02 | 76.60 | - | - |
P/OCF Ratio | 25.01 | 40.51 | 19.95 | 27.83 | 48.09 | 37.75 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.70 | 6.98 | 2.97 | 5.75 | 5.22 | 3.90 |
EV/EBITDA Ratio | 23.04 | 32.07 | 15.96 | 28.47 | 28.33 | 23.72 |
EV/EBIT Ratio | 34.77 | 46.74 | 23.81 | 42.17 | 38.83 | 29.43 |
EV/FCF Ratio | 28.80 | 52.05 | 27.50 | 64.19 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.05 | 0.04 | 0.09 | 0.04 | 0.01 |
Debt / EBITDA Ratio | 0.30 | 0.51 | 0.45 | 0.99 | 0.49 | 0.12 |
Debt / FCF Ratio | 0.37 | 0.82 | 0.78 | 2.24 | - | - |
Net Debt / Equity Ratio | -0.50 | -0.48 | -0.48 | -0.50 | -0.51 | -0.65 |
Net Debt / EBITDA Ratio | -5.59 | -5.06 | -5.21 | -5.76 | -5.76 | -8.83 |
Net Debt / FCF Ratio | -6.99 | -8.21 | -8.98 | -13.00 | 6.63 | 12.11 |
Asset Turnover | 0.37 | 0.37 | 0.40 | 0.35 | 0.40 | 0.39 |
Inventory Turnover | 1.50 | 1.61 | 1.97 | 1.50 | 1.63 | 1.56 |
Quick Ratio | 3.32 | 3.03 | 2.87 | 2.57 | 2.89 | 3.77 |
Current Ratio | 3.82 | 3.45 | 3.23 | 2.85 | 3.23 | 4.11 |
Return on Equity (ROE) | 8.76% | 9.54% | 8.99% | 8.98% | 10.41% | 10.60% |
Return on Assets (ROA) | 3.15% | 3.45% | 3.12% | 2.99% | 3.40% | 3.19% |
Return on Invested Capital (ROIC) | 10.54% | 12.27% | 11.80% | 11.39% | 14.74% | 19.36% |
Return on Capital Employed (ROCE) | 5.70% | 6.30% | 6.00% | 5.70% | 6.30% | 5.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.52% | 2.65% | 4.54% | 2.96% | 3.37% | 4.17% |
FCF Yield | 2.83% | 1.67% | 2.78% | 1.31% | -2.56% | -2.20% |
Dividend Yield | 1.10% | 0.80% | 1.46% | 0.94% | 0.96% | 1.78% |
Payout Ratio | 27.90% | 27.03% | 31.11% | 31.37% | 38.96% | 15.66% |
Buyback Yield / Dilution | 1.46% | 0.52% | 1.04% | -0.14% | -0.37% | -19.70% |
Total Shareholder Return | 2.57% | 1.32% | 2.50% | 0.80% | 0.59% | -17.92% |